Your browser is no longer supported. Please, upgrade your browser.
SUPN [NASD]
Supernus Pharmaceuticals, Inc.
Index- P/E13.41 EPS (ttm)2.36 Insider Own1.60% Shs Outstand52.71M Perf Week11.97%
Market Cap1.69B Forward P/E24.35 EPS next Y1.30 Insider Trans-12.02% Shs Float50.78M Perf Month19.80%
Income127.00M PEG7.93 EPS next Q0.24 Inst Own- Short Float14.45% Perf Quarter10.11%
Sales520.40M P/S3.24 EPS this Y12.60% Inst Trans1.69% Short Ratio12.06 Perf Half Y54.48%
Book/sh14.13 P/B2.24 EPS next Y28.66% ROA8.90% Target Price34.50 Perf Year69.52%
Cash/sh7.95 P/C3.99 EPS next 5Y1.69% ROE18.60% 52W Range17.20 - 32.31 Perf YTD25.99%
Dividend- P/FCF12.49 EPS past 5Y53.00% ROI11.70% 52W High-1.89% Beta1.27
Dividend %- Quick Ratio2.40 Sales past 5Y28.70% Gross Margin89.90% 52W Low84.30% ATR1.30
Employees563 Current Ratio2.60 Sales Q/Q43.00% Oper. Margin33.40% RSI (14)66.61 Volatility4.09% 4.60%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.50% Profit Margin24.40% Rel Volume0.55 Prev Close31.85
ShortableYes LT Debt/Eq0.49 Earnings- Payout0.00% Avg Volume608.42K Price31.70
Recom2.00 SMA2014.41% SMA5013.50% SMA20030.63% Volume336,141 Change-0.47%
Apr-13-21Upgrade Jefferies Hold → Buy $25 → $40
Jun-16-20Upgrade Piper Sandler Neutral → Overweight $25 → $31
Jun-15-20Resumed Jefferies Hold $24
Nov-08-19Downgrade Berenberg Buy → Hold
Nov-07-19Downgrade Stifel Buy → Hold $55 → $23
Nov-06-19Downgrade Jefferies Buy → Hold $46 → $23
Nov-12-18Reiterated B. Riley FBR Buy $68 → $65
Jan-18-18Reiterated B. Riley FBR, Inc. Buy $54
Dec-28-17Reiterated B. Riley FBR, Inc. Buy $50 → $54
Dec-04-17Upgrade Janney Neutral → Buy
Nov-08-17Upgrade Stifel Hold → Buy $47
Oct-19-17Initiated FBR & Co. Buy $53
Sep-19-17Downgrade Stifel Buy → Hold $47
Jul-17-17Downgrade Piper Jaffray Overweight → Neutral
Jul-14-17Initiated Janney Neutral
Jun-01-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-16Downgrade Piper Jaffray Overweight → Neutral
Jul-18-16Downgrade Northland Capital Outperform → Market Perform
Feb-08-16Upgrade Jefferies Hold → Buy
Nov-05-15Reiterated Northland Capital Outperform $26 → $27
Apr-05-21 08:07PM  
02:05PM  
01:16PM  
05:13AM  
05:08AM  
Apr-04-21 06:11AM  
Apr-02-21 04:58PM  
Mar-24-21 06:12AM  
Feb-27-21 06:15AM  
Feb-26-21 10:01AM  
09:00AM  
Feb-25-21 04:37PM  
04:00PM  
02:30PM  
12:03PM  
Feb-23-21 09:00AM  
Feb-22-21 08:00AM  
Feb-08-21 09:00AM  
Feb-04-21 04:10PM  
Feb-03-21 06:52AM  
Jan-25-21 02:20PM  
Jan-12-21 12:48PM  
Jan-06-21 05:29PM  
Dec-24-20 10:02AM  
05:02AM  
Dec-23-20 02:28PM  
10:41AM  
08:29AM  
12:48AM  
Dec-22-20 06:53PM  
06:07PM  
Dec-07-20 10:56AM  
09:48AM  
Nov-28-20 11:50PM  
Nov-27-20 11:00AM  
Nov-26-20 12:30AM  
Nov-23-20 10:00PM  
Nov-22-20 01:37AM  
Nov-19-20 03:30PM  
01:00PM  
Nov-18-20 10:00PM  
08:05PM  
07:18PM  
Nov-16-20 11:00PM  
Nov-14-20 03:00PM  
Nov-11-20 09:45PM  
12:00PM  
11:24AM  
Nov-10-20 08:40AM  
Nov-09-20 06:30PM  
09:30AM  
Nov-04-20 01:30PM  
07:15AM  
Nov-03-20 05:45PM  
04:30PM  
Oct-27-20 05:30PM  
Oct-13-20 01:13PM  
Oct-05-20 04:00PM  
Sep-28-20 10:01AM  
Sep-25-20 07:09AM  
Sep-24-20 07:10AM  
Sep-14-20 08:15AM  
Sep-09-20 04:30PM  
Sep-02-20 04:30PM  
Aug-19-20 12:00PM  
Aug-18-20 07:25PM  
06:06PM  
Aug-16-20 09:12AM  
Aug-12-20 07:29AM  
Aug-11-20 04:30PM  
Aug-10-20 08:36AM  
Jul-30-20 12:10PM  
Jul-28-20 12:33PM  
Jun-26-20 06:29PM  
Jun-19-20 01:47AM  
Jun-09-20 03:46PM  
Jun-02-20 10:00AM  
May-27-20 04:30PM  
May-15-20 04:15PM  
04:00PM  
May-09-20 04:17PM  
May-07-20 05:30PM  
May-05-20 08:25PM  
06:46PM  
Apr-30-20 09:40AM  
Apr-29-20 08:40AM  
Apr-28-20 05:00PM  
12:33PM  
Apr-24-20 04:30PM  
Apr-21-20 04:15PM  
Apr-15-20 11:21AM  
Mar-30-20 05:20PM  
Mar-16-20 10:34AM  
Mar-13-20 11:16AM  
Mar-09-20 01:30PM  
Feb-26-20 01:14PM  
09:36AM  
Feb-25-20 05:55PM  
04:40PM  
Feb-17-20 01:22PM  
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martin Tami TillotsonSr. V.P., Regulatory AffairsApr 14Option Exercise12.983,12540,56289,451Apr 14 08:24 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsApr 14Sale31.983,12599,93886,326Apr 14 08:24 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsApr 13Option Exercise12.983,12540,56289,451Apr 14 08:24 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsApr 13Sale29.983,12593,70286,326Apr 14 08:24 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 21Option Exercise12.9846,347601,58449,119Dec 22 05:49 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 21Sale22.1046,3471,024,4632,772Dec 22 05:49 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 14Option Exercise9.3953,653503,91656,425Dec 15 08:20 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 14Sale21.8753,6531,173,2642,772Dec 15 08:20 PM
PATRICK GREGORY SSr. VP Chief Financial OfficerNov 09Option Exercise12.985,00064,90049,463Nov 10 04:19 PM
PATRICK GREGORY SSr. VP Chief Financial OfficerNov 09Sale25.005,000125,00044,463Nov 10 04:19 PM
PATRICK GREGORY SSr. VP, CFONov 05Option Exercise12.985,00064,90049,463Nov 06 05:43 PM
PATRICK GREGORY SSr. VP, CFONov 05Sale23.005,000115,00044,463Nov 06 05:43 PM
PATRICK GREGORY SSr. VP, CFOOct 15Option Exercise12.9815,000194,70059,463Oct 15 06:04 PM
PATRICK GREGORY SSr. VP, CFOOct 15Sale20.0315,000300,50744,463Oct 15 06:04 PM
Hudson Frederick M.DirectorJul 13Option Exercise2.568,75022,40018,961Jul 15 04:39 PM
Hudson Frederick M.DirectorJul 13Sale24.4492022,48518,041Jul 15 04:39 PM
PATRICK GREGORY SSr.VP, Chief Financial OfficerMay 20Option Exercise12.9815,000194,70061,057May 20 06:59 PM
PATRICK GREGORY SSr.VP, Chief Financial OfficerMay 20Sale25.0315,000375,38046,057May 20 06:59 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerMay 08Option Exercise9.1315,000136,95061,057May 11 06:42 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerMay 08Sale23.1415,000347,03446,057May 11 06:42 PM